Compared with patients receiving anti-VEGF, patients receiving Pembrolizumab, Sintilimab, Toripalimab, Camrelizumab, or Tislelizumab had more sustained AKI events in one year (Supplementary Fig. 2). This evidence concerns the gene VEGFA and acute kidney injury.